Drugs / [177Lu]Lu-XT771
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07648823 | Jun 2026 → Jun 2027 expected | IDH-wildtype glioblastoma | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [177Lu]Lu-XT771 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07648823 ↗ |
| Modality | Other / unclassified | “investigational radiopharmaceutical” NCT07648823 ↗ |
| Route | Other | “The drug will be administered directly into the tumor resection cavity via a surgically implanted Ommaya reservoir” NCT07648823 ↗ |